Skip to main content
. 2019 May 23;8(5):737. doi: 10.3390/jcm8050737

Figure 5.

Figure 5

Network meta-analysis results of treatment efficacy in refractory/relapse (R/R) chronic lymphocytic leukemia (CLL): Forest plot of PFS in R/R CLL patients without del(17p) mutation. HR: Hazard ratio, CI: Confidence interval, SUCRA: Surface under the cumulative ranking curve, BR: Bendamustine + Rituximab, R: Rituximab.